|Bid||125.64 x 800|
|Ask||0.00 x 900|
|Day's range||124.82 - 126.58|
|52-week range||91.51 - 127.79|
|Beta (5Y monthly)||0.34|
|PE ratio (TTM)||38.30|
|Forward dividend & yield||1.60 (1.28%)|
|Ex-dividend date||12 Aug 2022|
|1y target est||129.29|
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
The FDA approves Rigel's (RIGL) Rezlidhia (olutasidenib) for treating relapsed/refractory acute myeloid leukemia with a susceptible IDH1 mutation. Stock up.
Until that day, companies in the healthcare sector that can stay ahead of the curve will continue to thrive. Although this market is competitive, the company made its name by targeting the life sciences industry. In other words, Veeva Systems is a specialist, not a generalist.